Literature DB >> 27212416

Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.

Melanie M Pleiss1, Pradoldej Sompol2, Susan D Kraner3, Hafiz Mohmmad Abdul4, Jennifer L Furman5, Rodney P Guttmann6, Donna M Wilcock7, Peter T Nelson8, Christopher M Norris9.   

Abstract

Mounting evidence suggests that astrocyte activation, found in most forms of neural injury and disease, is linked to the hyperactivation of the protein phosphatase calcineurin. In many tissues and cell types, calcineurin hyperactivity is the direct result of limited proteolysis. However, little is known about the proteolytic status of calcineurin in activated astrocytes. Here, we developed a polyclonal antibody to a high activity calcineurin proteolytic fragment in the 45-48kDa range (ΔCN) for use in immunohistochemical applications. When applied to postmortem human brain sections, the ΔCN antibody intensely labeled cell clusters in close juxtaposition to amyloid deposits and microinfarcts. Many of these cells exhibited clear activated astrocyte morphology. The expression of ΔCN in astrocytes near areas of pathology was further confirmed using confocal microscopy. Multiple NeuN-positive cells, particularly those within microinfarct core regions, also labeled positively for ΔCN. This observation suggests that calcineurin proteolysis can also occur within damaged or dying neurons, as reported in other studies. When a similar ΔCN fragment was selectively expressed in hippocampal astrocytes of intact rats (using adeno-associated virus), we observed a significant reduction in the strength of CA3-CA1 excitatory synapses, indicating that the hyperactivation of astrocytic calcineurin is sufficient for disrupting synaptic function. Together, these results suggest that proteolytic activation of calcineurin in activated astrocytes may be a central mechanism for driving and/or exacerbating neural dysfunction during neurodegenerative disease and injury.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Astrocytes; Calcineurin; Microinfarct; Proteolysis

Mesh:

Substances:

Year:  2016        PMID: 27212416      PMCID: PMC5026189          DOI: 10.1016/j.bbadis.2016.05.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  92 in total

1.  Astrocytic gliosis in the amygdala in Down's syndrome and Alzheimer's disease.

Authors:  G M Murphy; W G Ellis; Y L Lee; K E Stultz; R Shrivastava; J R Tinklenberg; L F Eng
Journal:  Prog Brain Res       Date:  1992       Impact factor: 2.453

2.  Pathological alterations in the amygdala in Alzheimer's disease.

Authors:  L J Kromer Vogt; B T Hyman; G W Van Hoesen; A R Damasio
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

Review 3.  Reactive astrocytes: cellular and molecular cues to biological function.

Authors:  J L Ridet; S K Malhotra; A Privat; F H Gage
Journal:  Trends Neurosci       Date:  1997-12       Impact factor: 13.837

4.  Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Mubeen A Ansari; Kelly N Roberts; Frederick A Schmitt; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Glial dysfunction in the mouse habenula causes depressive-like behaviors and sleep disturbance.

Authors:  Wanpeng Cui; Hiroaki Mizukami; Michiko Yanagisawa; Tomomi Aida; Masatoshi Nomura; Yoshikazu Isomura; Ryoichi Takayanagi; Keiya Ozawa; Kohichi Tanaka; Hidenori Aizawa
Journal:  J Neurosci       Date:  2014-12-03       Impact factor: 6.167

6.  Aβ leads to Ca²⁺ signaling alterations and transcriptional changes in glial cells.

Authors:  Ambra A Grolla; Gohar Fakhfouri; Giulia Balzaretti; Elena Marcello; Fabrizio Gardoni; Pier L Canonico; Monica DiLuca; Armando A Genazzani; Dmitry Lim
Journal:  Neurobiol Aging       Date:  2012-06-05       Impact factor: 4.673

7.  The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit.

Authors:  Andy Y Shih; Pablo Blinder; Philbert S Tsai; Beth Friedman; Geoffrey Stanley; Patrick D Lyden; David Kleinfeld
Journal:  Nat Neurosci       Date:  2012-12-16       Impact factor: 24.884

8.  Synapse stability in the precuneus early in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Kelly N Roberts; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Activity-dependent NFATc3 nuclear accumulation in pericytes from cortical parenchymal microvessels.

Authors:  Jessica A Filosa; Mark T Nelson; Laura V Gonzalez Bosc
Journal:  Am J Physiol Cell Physiol       Date:  2007-09-19       Impact factor: 4.249

10.  Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.

Authors:  Hafiz Mohmmad Abdul; Michelle A Sama; Jennifer L Furman; Diana M Mathis; Tina L Beckett; Adam M Weidner; Ela S Patel; Irfan Baig; M Paul Murphy; Harry LeVine; Susan D Kraner; Christopher M Norris
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

View more
  17 in total

1.  Astrocyte mitochondria: Central players and potential therapeutic targets for neurodegenerative diseases and injury.

Authors:  J L Gollihue; C M Norris
Journal:  Ageing Res Rev       Date:  2020-02-24       Impact factor: 10.895

Review 2.  An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia.

Authors:  Brittani R Price; Christopher M Norris; Pradoldej Sompol; Donna M Wilcock
Journal:  J Neurochem       Date:  2018-01-22       Impact factor: 5.372

3.  Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice.

Authors:  Pradoldej Sompol; Jennifer L Furman; Melanie M Pleiss; Susan D Kraner; Irina A Artiushin; Seth R Batten; Jorge E Quintero; Linda A Simmerman; Tina L Beckett; Mark A Lovell; M Paul Murphy; Greg A Gerhardt; Christopher M Norris
Journal:  J Neurosci       Date:  2017-05-30       Impact factor: 6.167

Review 4.  A central role for calcineurin in protein misfolding neurodegenerative diseases.

Authors:  Syed Zahid Ali Shah; Tariq Hussain; Deming Zhao; Lifeng Yang
Journal:  Cell Mol Life Sci       Date:  2016-09-28       Impact factor: 9.261

5.  Calcineurin: directing the damage in Alzheimer disease: An Editorial for 'Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain' on page 24.

Authors:  Christopher M Norris
Journal:  J Neurochem       Date:  2018-09-07       Impact factor: 5.372

6.  Calcineurin-Mediated Hippocampal Inflammatory Alterations in Streptozotocin-Induced Model of Dementia.

Authors:  João Paulo Almeida Dos Santos; Adriana Fernanda Vizuete; Carlos-Alberto Gonçalves
Journal:  Mol Neurobiol       Date:  2019-08-06       Impact factor: 5.590

7.  Astrocytes mediated the nootropic and neurotrophic effects of Sarsasapogenin-AA13 via upregulating brain-derived neurotrophic factor.

Authors:  Dong Dong; Yu Mao; Cui Huang; Qian Jiao; Hui Pan; Lei Ma; Rui Wang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 8.  Detection, risk factors, and functional consequences of cerebral microinfarcts.

Authors:  Susanne J van Veluw; Andy Y Shih; Eric E Smith; Christopher Chen; Julie A Schneider; Joanna M Wardlaw; Steven M Greenberg; Geert Jan Biessels
Journal:  Lancet Neurol       Date:  2017-07-14       Impact factor: 44.182

9.  Calcineurin A beta deficiency ameliorates HFD-induced hypothalamic astrocytosis in mice.

Authors:  Katrin Pfuhlmann; Sonja C Schriever; Beata Legutko; Peter Baumann; Luke Harrison; Dhiraj G Kabra; Emily Violette Baumgart; Matthias H Tschöp; Cristina Garcia-Caceres; Paul T Pfluger
Journal:  J Neuroinflammation       Date:  2018-02-08       Impact factor: 8.322

10.  I2 imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin pathway.

Authors:  Foteini Vasilopoulou; Christian Griñán-Ferré; Sergio Rodríguez-Arévalo; Andrea Bagán; Sònia Abás; Carmen Escolano; Mercè Pallàs
Journal:  Geroscience       Date:  2020-10-31       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.